Abbvie Inc ABBV

$295.03 +0.58 (0.20%)

Valuation

Market cap
521,499,712,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.95
P/E (forward)
21.06
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
3,262,100
Avg volume
4,951,810
Day's range
$293.56 – $297.25
Shares out
1,767,616,000
Stochastic %K
64%
Beta
0.20
Analysts
Moderate Buy
Price target
$309.60

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Nov 16, 5:27 AM
$SLS $MRNA $XBI $ABBV Buying Opportunity of a Lifetime. --- OCV501 a Weaker WT1 Peptide Vaccine 5 year Data - the 30% of Patients who Responded had Extended Overall Survival -- Key UNBLINDED Data from the GPS INTERIM ANALYSIS 80% + of GPS P3 Patients Responded. - 80% of Randomly Selected REGAL GPS Patients Showed a Specific T-Cell immune Response, Surpassing the Results From the Previous Phase 2 Study - Note the Top Line Solid Black are Responders / 33% of the trial - GPs P3 Results of 80% + RESPONSE, ALONG 7 PRIOR GPS TRIAL RESULTS, GUARANTEES GPS WILL BE FDA APPROVED and SLS IS WORTH 27X + the CURRENT MARKET PRICE. OCV was a weaker single, HLA Restricted heterclitic WT1 vaccine. IF it had 80% response Like GPS, it would have been FDA Approved and Used in Every Blood Cancer Clinic on the Planet - LIKE GPS WILL BE.
0 replies
Techdamentals Nov 16, 2:19 AM
The S&P 500 rose 2.5% for the week ended Friday, November 13, 2026, and this week brings earnings from Nvidia, Home Depot, Walmart and more. One number from $ABBV's latest report: net revenues rose 10.3% to $17.404 billion in the quarter ended September 30, 2026, from $15.776 billion a year earlier. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/ABBV?ref=st
0 replies
55X_ROI_Q1_2026 Nov 15, 11:09 PM
$SLS $XBI $MRNA GPS Specific Immune Response Rate in 80% of Tested Gps Patients in the actual Phase 3 Trial. 80% IR Immune Response is directly correlated w Increased Survival. It is not complicated. BAT / FAILED TO INCREASE SURVIVAL IN 5 Large Clinical Trials, including 2 Phase 3 AML REMISSION Trials conducted by $ABBV VIALE-T and VIALE-M FAILED. //
0 replies
55X_ROI_Q1_2026 Nov 15, 10:34 PM
$SLS $MRNA $XBI $ABBV https://www.mdpi.com/2072-6694/15/5/1458 IDMC Unblinded Actual Phase 3 REGAL Trial Data from the Interim Analysis: • GPS Specific Immune Response of 80% of Gps Patients. Immune Response is Directly correlated with Increased Survival - in all prior Gps trials. Cancers 2023 Submission received: 19 January 2023 / Revised: 19 February 2023 / Accepted: 22 February 2023 / Published: 25 February 2023
0 replies
harmongreg Nov 15, 3:10 PM
5 Trade Ideas for Monday: AbbVie, BlackRock, BoNY, Cencora and CSX $ABBV $BLK $BNY $COR $CSX https://dragonflycap.com/5-trade-ideas-for-monday-abbvie-blackrock-bony-cencora-and-csx/
0 replies
55X_ROI_Q1_2026 Nov 15, 1:14 AM
$SLS @Forestbird what is even cooler, is GPs Has Already Proven Effective in First Remission (CR1) - Phase 2 AML Data Published at ASH Median OS was not yet reached and greater than > 67.6 Months. with a Limited Dosing regime in just the first 9 months. 67.6 month MOS in CR1 Standard of Care / Onureg MOS is just 24.7 months in CR1 Adding Venetoclax to Onureg FAILED to increase survival in 5 Recent Trials, including the VIALE-M Phase 3 Trial conducted by $ABBV for the same exact CR1 setting. it is not complicated.
2 replies
55X_ROI_Q1_2026 Nov 14, 8:12 PM
$SLS $MRNA $XBI How many of the Short and Idiot Inch Thick Retail Know Adding VENETOCLAX to ORAL Aza FAILED in 5 Recent Trials? • BAT for AML First Remission Maintenance is ONUREG/ ORAL Az MOS of 24.7 Months --- Gps Phase 2 trial in the same Setting > 67.6 months. Adding Venetoclax to Oral Az FAILED the VIALE-M Phase 3 Trial Conducted by $ABBV for AML First Remission (CR1) Patients. Adding Venetoclax to Oral Az FAILED the VIALE-T Phase 3 Trial Conducted by $ABBV for AML POST TRANSPLANT MAINTENANCE. VERONA P3 FAILED - High Risk MDS/ AML OPTI_AML FAILED - LOW DOSE COMBO'S FAILED PARADIGM FAILED to INCREASE OS even though more obtained Remission.
0 replies
SellasgpsCurativeBAT11 Nov 14, 4:12 PM
$ABBV $BMY $JNJ $PFE $SLS 👇 ✌️🙏❤️‍🩹
0 replies